S100A11 and idiopathic pulmonary fibrosis: Moreover, MR analysis of protein level ratio, mediator MR analysis, enrichment, and PPI network provided insights into the potential drug development based on the proteins.<h4>Conclusions</h4>Our proteome-wide Mendelian Randomization analysis highlighted MASP1, S100A11, and WFIKKN2 as potential targets for further clinical investigation in IPF.